louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04131868: Sleep and Girls' Emotions Study
Official title: The Contribution of Stressful Life Events and Insufficient Sleep to Reward-Related Brain Function and Depression in Adolescent Girls
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Lead sponsor: University of Oregon
Sponsor class: OTHER
First posted: 2019-10-18
Enrollment: 34
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 22
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study evaluates whether increasing sleep duration can increase neural and behavioral response to rewards and decrease depressive symptoms in 18- to 22-year-old women with insufficient sleep and depressive symptoms.


Eligibility criteria: Inclusion Criteria:

* Insufficient sleep (total sleep time \< 8 hours per night, with sleepiness scores ≥ 6 on the Epworth Sleepiness Scale OR ≥ 16 on the PROMIS Sleep Related Impairment Scale)
* Symptoms of depression (≥ 15 on the Center for Epidemiological Studies for Depression Scale)

Exclusion Criteria:

* Current insomnia, hypersomnia, sleep disordered breathing, sleep movement disorder, or circadian rhythm disorder
* History of head injury with loss of consciousness within the past two years
* History of head injury with loss of consciousness two or more years ago and meet criteria for post concussion syndrome
* Neurological disorder
* Use of psychiatric medications
* Current psychotic symptoms
* Active suicidal ideation
* Conditions that are contraindicated for MRI (e.g., ferromagnetic material in the body)
* Meet criteria for current substance use disorder with greater than mild severity

Primary outcomes:
measure: Depressive symptoms
timeFrame: 1 week
measure: Reward-related brain function
timeFrame: 1 week
measure: Sleep duration
timeFrame: 1 week
Secondary outcomes:
measure: Positive affect
timeFrame: 1 week
measure: Negative affect
timeFrame: 1 week
measure: Reward effort
timeFrame: 1 week
measure: Reward-related functional connectivity
timeFrame: 1 week
Other outcomes:
Locations:
city: Eugene
country: United States
facility: University of Oregon
state: Oregon
Study officials:
affiliation: University of Oregon
name: Melynda D Casement, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02896868: A Study of LY3041658 in Participants With Skin Diseases
Official title: A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Skin Diseases
Psoriasis
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2016-09-12
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The main purpose of this study is to investigate the safety and tolerability of the study drug known as LY3041658 in participants with certain types of skin diseases. The study will measure how the body absorbs, breaks down and gets rid of LY3041658. It will last about 127 days for each participant, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.


Eligibility criteria: Inclusion Criteria:

* Investigator confirmed diagnosis of certain skin diseases for at least 6 months.
* Active skin lesions that are not responding to standard therapies.
* Willing to undergo pre- and post-treatment skin biopsies of lesions.

Exclusion Criteria:

- Have other skin diseases that may interfere with evaluation of the specified skin disease being studied.

Primary outcomes:
measure: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
timeFrame: Dosing Day 1 through Day 127
Secondary outcomes:
measure: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3041658
timeFrame: Dosing Day 1 through Day 127
measure: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) During Dosing Interval at Steady State (AUCss) of LY3041658
timeFrame: Dosing Day 1 through Day 127
measure: Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of LY3041658
timeFrame: Dosing Day 1 through Day 127
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Parexel Early Phase Unit at Glendale
state: California
city: Indianapolis
country: United States
facility: Dawes Fretzin Clinical Research
state: Indiana
city: Baltimore
country: United States
facility: PAREXEL-Phase 1 Baltimore Harbor Hospital Center
state: Maryland
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Duncansville
country: United States
facility: Altoona Center for Clinical Research
state: Pennsylvania
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT01626768: Medtronic Market-Released DF4 Lead Imaging
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tachycardia
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure
Sponsor class: INDUSTRY
First posted: 2012-06-25
Enrollment: 37
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients followed at participating centers.

Brief summary: The Medtronic Market-Released DF4 Lead Imaging Study is a prospective, non-randomized study, multi-center clinical investigation.

The purpose of this clinical investigation is to collect high quality medical images of the Medtronic Market-Released DF4 lead in the shoulder and heart. Images collected during the study will allow for lead design and testing processes better tailored to the implanted environment.


Eligibility criteria: Inclusion Criteria:

* Patients greater than 18 years of age.
* Patients able and willing to attend imaging session.
* Patients able and willing to give informed consent.
* Patients with an implanted device/lead(s) for a minimum of 3 months.

Exclusion Criteria:

* Subjects who require a legally authorized representative to obtain consent.
* Subjects with exclusion criteria required by local law (e.g. age, breastfeeding
* Pregnant women, or women of child bearing potential and who are not on a reliable form of birth control.

Primary outcomes:
measure: In vivo lead shape
timeFrame: Six Months
Secondary outcomes:
Other outcomes:
Locations:
city: Riyadh
country: Saudi Arabia
city: London
country: United Kingdom
Study officials:
References:
Clinical trial NCT06165068: Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study
Official title: Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Dry Age-related Macular Degeneration
Lead sponsor: Navamindradhiraj University
Sponsor class: OTHER
First posted: 2023-12-11
Enrollment: 174
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 1. Aspirin 81 mg/d or Clopidogrel 75 mg/d
2. Aspirin 81 mg/d or Clopidogrel 75 mg/d with N-acetylcysteine 600 mg/d
3. No medication
Primary purpose: PREVENTION

Brief summary: The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry AMD patient with large drusen.

Participants will divided in to three groups.

* Participants who were already taking low dose antiplatelet medications.
* Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator
* Participants does not use any medications.


Eligibility criteria: Inclusion Criteria:

* Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron.
* Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity.
* Age range: 50-85 years
* Patients who have previously used antiplatelet drugs.

Exclusion Criteria:

* Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization)
* Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema.
* Patient with a history of intravitreal anti-VEGF injection or macular laser.
* Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.

Primary outcomes:
measure: Drusen volume analysis
timeFrame: 1 year
Secondary outcomes:
measure: Best-corrected visual acuity change
timeFrame: 1 year
measure: Rate of disease progression
timeFrame: 1 year
measure: Side effects of medications intake
timeFrame: 1 year
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Department of ophthalmology, Faculty of medicine, Vajira hospital, Navamindradhiraj University
state: Dusit
Study officials:
References:
Clinical trial NCT05888168: Predictors of Postoperative Atrial Fibrillation After CABG
Official title: A Comprehensive Observational Study on the Determinants of Postoperative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Coronary Artery Disease
Atrial Fibrillation New Onset
Keywords: coronary artery bypass grafting
postoperative atrial fibrillation
Lead sponsor: Beijing Anzhen Hospital
Sponsor class: OTHER
First posted: 2023-06-05
Enrollment: 15000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The participants in this study are adult patients (18 years and older) who have undergone Coronary Artery Bypass Grafting (CABG). These individuals come from diverse demographic backgrounds and have a history of severe coronary heart disease, the condition that necessitated the CABG surgery.

Brief summary: This observational study aims to identify the determinants or predictors of postoperative atrial fibrillation (POAF) in patients who have undergone coronary artery bypass grafting (CABG). The study will compare two cohorts: patients who developed POAF and those who did not (non-POAF), with the aim of improving postoperative care, reducing complications, and refining patient risk stratification.

Detailed description: Demographics (age, sex, ethnicity), lifestyle factors (smoking, alcohol, physical activity), and medical history (diabetes, hypertension, prior heart diseases) will be recorded. Surgical procedure details (number of grafts, use of intraoperative devices), anesthesia, and medications administered. Levels of inflammatory markers, cardiac-specific markers, and other relevant biomarkers at baseline and postoperatively. Other complications besides POAF, hospital length of stay, ICU admission, readmission rate, and mortality will also be monitored.

Eligibility criteria: Inclusion Criteria:

* Adults aged 18 years or older.
* Patients who underwent CABG.

Exclusion Criteria:

* Patients with a history of preoperative atrial fibrillation or other significant arrhythmias.
* Patients who underwent other concurrent cardiac procedures (e.g., valve surgery) in addition to CABG.
* Patients who cannot provide informed consent or lack adequate follow-up information.

Primary outcomes:
measure: Incidence of POAF
timeFrame: During hospital stay, up to 30 days
Secondary outcomes:
measure: Hospital length of stay
timeFrame: During hospital stay, up to 30 days
measure: ICU admission time
timeFrame: During hospital stay, up to 30 days
measure: Number of participants with Stroke
timeFrame: During hospital stay, up to 30 days
measure: Mortality
timeFrame: During hospital stay, up to 30 days
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Anzhen Hospital
Study officials:
affiliation: Beijing Anzhen Hospital
name: Kun Hua, MD
role: STUDY_CHAIR
References:
Clinical trial NCT03572868: Long-term Outcome of Newborns With an Isolated Small Cerebellum
Official title: Perinatal and Long-term Outcome of Newborns With an Isolated Small Transverse Cerebellar Diameter
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cerebellar Hypoplasia
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2018-06-28
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Parents of newborns who have an isolated transverse cerebellar diameter \< 5th centile during the 2nd or the 3rd trimester ultrasound examination realized at the hospital Femme Mère Enfant in Lyon between 2008 and 2015.

Brief summary: The decreased cerebellar biometry during second and third trimester ultrasound examination is the main parameter to diagnoses cerebellar and pontocerebellar hypoplasia. Investigators already described that a transverse cerebellar diameter (TCD) below the 5th centile at second or third trimester scan is related to a high rate of fetal malformations, severe intrauterine restriction in growth, chromosomal anomalies and genetic disorders, therefore when facing a TCD below the 5th centile, patients should be referred for oriented sonogram, fetal MRI (Magnetic resonance imaging) and fetal karyotyping.

However, prenatal counseling in case of an isolated decreased cerebellar biometry remains challenging since there are no data in the literature regarding the neurodevelopmental outcome of these newborns. The aim of this work is to evaluate the neurodevelopmental outcome of newborns with a prenatal isolated decreased cerebellar biometry, in order to improve prenatal counseling.


Eligibility criteria: Inclusion Criteria:

* 2nd or the 3rd trimester ultrasound examination realized at the hospital "Femme Mère Enfant" in Lyon between 2008 and 2015
* Isolated Transverse cerebellar diameter \<5th centile
* Parents who received the information and did not object to participate to the study

Exclusion Criteria:

* Decreased Transverse cerebellar diameter with associated malformations diagnosed during prenatal period
* Family history of neurodevelopmental delay or cognitive impairment
* Preterm delivery (\< 28 WG)
* Severe restriction in growth at birth (\<3e centile)
* Neonatal asphyxia (pH blood cord \< 7)
* Apgar score \< 7 at 5 min of live with transfer to the neonatal intensive care unit

Primary outcomes:
measure: Development Quotient.
timeFrame: between 3 and 10 years after birth
Secondary outcomes:
Other outcomes:
Locations:
city: Bron
country: France
facility: Service Obstétrique - Hôpital Femme Mère Enfant - Groupement Hospitalier Est
Study officials:
References:
Clinical trial NCT01618968: Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device
Official title: Exposure, Safety and Local Tolerance Study Comparing the Relative Bioavailability of Oral Methotrexate and the VIBEX™ MTX Device in Adult Subjects With Rheumatoid Arthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Rheumatoid Arthritis (RA)
Lead sponsor: Antares Pharma Inc.
Sponsor class: INDUSTRY
First posted: 2012-06-14
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Relative Bioavailability Comparison study

Detailed description: A Phase 2, Open-Label, Randomized, 3-Way Crossover Study to Compare the Relative Bioavailability of Oral Methotrexate and the VIBEX™ MTX Device in Adult Subjects With Rheumatoid Arthritis

Eligibility criteria: Inclusion Criteria:

* Male or female patients ≥18 years of age, diagnosed with Rheumatoid Arthritis

Exclusion Criteria:

* Pregnant females
* Any other clinically significant disease or disorder which, in the opinion of the investigator might put the subject at risk

Primary outcomes:
measure: Dose-Normalized AUC[0-Inf] for MTX
timeFrame: 24 Hour period
measure: Dose-Normalized AUC[0-24] for MTX
timeFrame: 24 Hour period
measure: Dose-Normalized Cmax for MTX
timeFrame: 24 Hour period
Secondary outcomes:
Other outcomes:
Locations:
city: Duncansville
country: United States
facility: Altoona Center for Clinical Research
state: Pennsylvania
Study officials:
affiliation: Altoona Center for Clinical Research
name: Alan J Kivitz, MD;CPI
role: PRINCIPAL_INVESTIGATOR
References:
citation: Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses >/=15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014 Aug;73(8):1549-51. doi: 10.1136/annrheumdis-2014-205228. Epub 2014 Apr 12.
Clinical trial NCT02125968: Therapeutic Effects of Video Game Play Therapy on Patients With Chronic Low Back Pain
Official title: Therapeutic Effects of Video Game Play Therapy on Patients With Chronic Low Back Pain:Randomized-Controlled Clinical Trail
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Chronic Low Back Pain
Keywords: chronic low back pain
video game
therapeutic effects
Lead sponsor: Taipei Medical University
Sponsor class: OTHER
Collaborators: name: Shin Kong Wu Ho-Su Memorial Hospital
First posted: 2014-04-29
Enrollment: 70
Sex: ALL
Minimum age (years): 20
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the video game play therapy in patients with chronic low back pain.

Detailed description: Understanding the short- and medium-term therapeutic effects of video game play therapy for patients with chronic low back pain.

Eligibility criteria: Inclusion Criteria:

* chronic low back pain

Exclusion Criteria:

1. low back pain accompanied by specific pathological conditions, such as infection, inflammation, fracture, or tumor
2. history of low back surgery with an implant
3. pregnancy of plans to become pregnant during the course of study
4. having received concurrent treatment for low back pain followed by another health care professional

Primary outcomes:
measure: Oswestry Disability Questionnaire
timeFrame: changes from baseline at one and three months after treatment
Secondary outcomes:
measure: range of motion
timeFrame: changes from baseline at one and three months after treatment
measure: Hospital Anxiety and Depression Scale
timeFrame: changes from baseline at one and three months after treatment
measure: postural stability
timeFrame: changes from baseline at one and three months after treatment
measure: Fear avoidance Behavior Questionnaire
timeFrame: changes from baseline at one and three months after treatment
measure: physical activity
timeFrame: changes from baseline at one and three months after treatment
Other outcomes:
Locations:
city: Taipie
country: Taiwan
facility: Shin Kong Wu Ho-Su Memorial Hospital
Study officials:
affiliation: Shin Kong Wu Ho-Su Memorial Hospital
name: Ru-Lan Hsieh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01994668: Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects
Official title: A Phase 1, Randomized Single-blind (Subject-blind), Placebo Controlled Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: lorazepam
intravenous
pharmacolinetics
healthy
Japanese
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2013-11-26
Enrollment: 8
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of 2-mg lorazepam intravenous administration in healthy Japanese adult subjects.


Eligibility criteria: Inclusion Criteria:

* Healthy Japanese male and/or female subjects of non-childbearing potential.
* Body Mass Index of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg.

Exclusion Criteria:

* History of sensitivity to lorazepam or other benzodiazepines.
* Evidence or history of acute narrow-angle glaucoma or sleep apnea syndrome.
* Significant psychiatric disorder, recurrent episodes of severe depression, or subjects with serious suicidal risk.

Primary outcomes:
measure: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs).
timeFrame: Day 1 to Day 4
Secondary outcomes:
measure: Maximum Observed Plasma Concentration (Cmax)
timeFrame: Day 1
measure: Area under the Concentration-Time Curve (AUC)
timeFrame: Day1 to Day 4
Other outcomes:
Locations:
city: Hachioji-shi
country: Japan
facility: Pfizer Investigational Site
state: Tokyo
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00139568: An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation
Official title: An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Constipation
Keywords: Chronic constipation
5-HT,5-HT4,
functional GI
China
tegaserod
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-08-31
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Tegaserod is an aminoguanidine indole compound and a member of a new class of 5-hydroxytryptamine (5-HT) agonists. Activation of 5-HT4 receptors triggers the release of neurotransmitters from the enteric nerves which in turn stimulate contractility and peristalsis. This study will investigate the efficacy and safety of tegaserod against chronic constipation in a Chinese population of adult men and women


Eligibility criteria: Inclusion Criteria:

* Men or women at least 18 years of age
* History of constipation for at least 6 months prior to screening
* Normal bowel evaluation performed within the past 5 years

Exclusion Criteria:

* Most bothersome symptom in last 6 months is abdominal pain/discomfort
* Whose chronic constipation is thought to be a result of bowel surgery, gynecological surgery, neurologic disorder, systemic sclerosis, amyloidosis, scleroderma, myotonic dystrophy
* Insulin dependent diabetes
* Evidence of cathartic colon or laxative abuse

Other inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Change from baseline in number of complete spontaneous bowel movements (CSBM) per week
Secondary outcomes:
measure: Response rate for CSBM during the first 4 weeks of treatment
measure: Patients' daily assessment of bowel habits
measure: Patients' weekly assessment of constipation symptoms
measure: Satisfactory relief of CC symptoms
measure: PAC-QoL questionnaire
measure: PPSM questionnaire
measure: Safety
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Novartis
Study officials:
affiliation: Novartis Basel, Switzerland
name: Novartis
role: STUDY_CHAIR
References: